The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a major regulatory setback, Lantheus received a Complete Response Letter (CRL) from the U.S. FDA for its experimental agent LNTH-2501, according to reports. The CRL indicates the application cannot be approved in its current form, often meaning deficiencies or additional data are required. This regulatory hurdle could significantly delay the drug's potential market entry and revenue generation.
A CRL typically signals that the FDA requires more information or identifies deficiencies, prolonging the approval process. The news arrives amid rising competition in the radiopharmaceutical sector, and market reaction is expected to be negative, putting further pressure on Lantheus stock.
Sign in to access this content
Sign InLNTH closed at $109.01 on June 25, 2026, and is likely to face selling pressure in the coming sessions as the market digests the news. Investors will watch for any clarification from Lantheus on its plan to address the FDA's concerns, as well as any updates on the revised development timeline.